Ethical Dilemmas Contribute To ‘Critical Weaknesses’ In FDA Postmarket Oversight


Ethical challenges are central to persistent “critical weaknesses” in the national system for ensuring drug safety, according to a commentary by former Institute of Medicine members published in the New England Journal of Medicine.

Read more

Posted in Drugs Glucose & Insulin Other News Type I Type II